HAVANA, Feb 11 The Cuban biopharmaceutical industry produced the first batch of 150,000 vial bottles of Soberana 02, the most advanced Covid-19 vaccine candidate,
which will start phase III of clinical trials in March, the developers highlighted. The large-scale production of the Cuban vaccine is aimed at providing sufficient doses to carry out the third phase of the study, according to the Twitter account of the Finlay Institute of Vaccines (IFV).
The second batch is already being produced, IFV Director Vicente Verez said at a recent meeting between the Government and scientists, a fact that he also described as an important scientific-technological milestone.
Currently, in expanded phase II, the second Covid-19 candidate developed by the institution showed great safety and powerful immune response. It induces long-term memory of the immune response, which, in addition to producing antibodies, makes them last, Verez noted regarding the results of the product.
The second period of clinical trials of Soberana 02 began on December 22, making it the first Latin American vaccine candidate to reach that stage, with nearly 900 volunteers participating in it.
On her Twitter account, IFV Research Director Dagmar Garcia highlighted the publication of the first preprint of the preclinical evaluation of the Cuban Soberana 02 vaccine in the bioRxiv specialized journal, demonstrating the scientific evidence of the second stage.(PL)